Compare Archer Aviation Inc (ACHR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Archer Aviation IncTrade

Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Archer Aviation Inc vs Recursion Pharmaceuticals Inc — how do they compare? Archer Aviation Inc trades at $6.45 (market cap $5.23B), while Recursion Pharmaceuticals Inc trades at $3.33 (market cap $1.81B). The key difference: Archer Aviation Inc is far larger — about 2.9× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

	ACHR	RXRX
Market Cap	$5.23B	$1.81B
Sector	Industrials	Health
52-Week High	$13.64	$6.79
52-Week Low	$4.44	$2.84
Enterprise Value	$3.79B	$1.33B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ACHR

Archer Aviation nears commercialization with strong growth and undervalued stock despite recent gainsSeeking Alpha · 22 hours agoBullish Archer Aviation stock jumps 11% on Boeing deal details and strong Q2 revenue growth24/7 Wall Street · 1 day agoBullish Red Cat shares jump 6.84% post-earnings despite revenue miss, driven by strong growth and sector momentum.24/7 Wall Street · 1 day agoBullish View details →

RXRX

Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships.Seeking Alpha · 1 day agoBearish View details →

About Archer Aviation Inc

Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.